Thermedical, a privately held company currently developing a proprietary ablation therapy for the treatment of cancer, announced today that it has received a $3 million Competing Phase 2 Renewal Grant from the National Cancer Institute. The three-year grant will fund continued development and testing of the company’s Saline Enhanced Radiofrequency Ablation (SERF) system, which is designed for use in ablation of malignant tumors.
